Karyopharm (KPTI) Q2 2026 earnings review
EC-042 Fails as the September Default Clock Ticks
Karyopharm is fighting for its life. The highly anticipated Phase 3 EC-042 trial in endometrial cancer failed its primary endpoint, destroying a critical pillar of the company's growth narrative. Consequently, management is halting investment in the program and betting the company's survival entirely on an August accelerated approval submission for selinexor in myelofibrosis. Meanwhile, the balance sheet is at a breaking point: a $15.8M debt payment due September 10 will likely trigger a $10M minimum liquidity covenant default unless a strategic alternative or waiver is secured immediately.
🐂 Bull Case
The FDA provided written feedback that spleen volume reduction (SVR35) qualifies as a reasonably likely surrogate endpoint for overall survival, clearing the path for an August sNDA submission for selinexor in MF.
U.S. XPOVIO net product revenue grew slightly YoY to $30.8M amidst intense competition, proving the drug maintains a sticky community oncology footprint (60% of sales).
🐻 Bear Case
Cash drops to critical levels by September 10. Making the $15.8M term loan payment will push cash below the $10M minimum liquidity covenant, triggering a default without an immediate restructuring.
The Phase 3 XPORT-EC-042 trial in endometrial cancer failed to meet its progression-free survival primary endpoint. The company has essentially written off a massive future TAM.
⚖️ Verdict: 🔴🔴
Very Bearish. The catastrophic combination of a major late-stage trial failure and an explicit, management-guided threat of a debt default within 30 days overrides any optimism regarding the myelofibrosis FDA submission.
Key Themes
XPORT-EC-042 Trial Fails
The Phase 3 XPORT-EC-042 trial evaluating selinexor in TP53 wild-type endometrial cancer failed to meet its primary endpoint for progression-free survival (median PFS 12.75 months vs 7.43 months for placebo, p=0.0791). This is a devastating blow. Management touted this as a multi-billion dollar expansion opportunity in previous quarters. Now, investment is being redirected entirely to myelofibrosis, wiping out significant future value.
The September Liquidity Cliff
Management was explicit: making the required $15.8M principal payment on September 10, 2026, will cause the company to breach its $10.0M minimum liquidity covenant, constituting an event of default on its senior secured term loan. Centerview Partners is actively evaluating financing or strategic alternatives, meaning the company is essentially operating under distressed restructuring conditions.
SENTRY Trial Accelerated Approval Path
Despite previously missing the co-primary endpoint for symptom score (TSS), the FDA agreed that SVR35 (spleen volume reduction) appears to qualify as a reasonably likely surrogate endpoint for overall survival. This enables an August sNDA submission. If approved, selinexor + ruxolitinib would be the first combination therapy for myelofibrosis, establishing a critical new lifeline for the company.
Macro Headwinds in Multiple Myeloma
The core commercial setting remains hostile. Management explicitly noted that U.S. demand for XPOVIO was 'relatively consistent' amidst a 'highly competitive commercial landscape.' The influx of novel bispecifics and CAR-T therapies in multiple myeloma continues to permanently cap selinexor's volume growth, forcing Karyopharm to rely entirely on gross-to-net optimizations to extract any revenue gains.
International Royalty Expansion
Ex-U.S. expansion remains a minor but accelerating bright spot. Royalty revenue from partners (Menarini, Antengene) grew 56% YoY from $1.6M in 25Q2 to $2.5M in 26Q2 as selinexor approvals surpassed 50 countries. This high-margin revenue slightly offsets the decline in milestone payments.
Toxic Debt Structure & Non-Cash Hits
While operating loss was a manageable $22.5M, total net loss ballooned to $67.0M. This was driven by a staggering $32.1M non-cash expense from the remeasurement of embedded derivatives and warrants linked to 2024/2025 refinancing deals, plus $13.1M in interest expense. The debt structure is actively destroying shareholder value.
OpEx Discipline Continues
Management successfully reduced Q2 SG&A by 9% YoY (to $25.9M) and R&D by 11.6% YoY (to $29.0M). Pre-launch investments are being heavily restricted to align with the company's dire balance sheet realities, though these savings are mathematically insufficient to bridge the September liquidity gap.
Other KPIs
Stable YoY (up from $29.7M in 25Q2). The community oncology channel consistently drives 60% of this figure, but the lack of sequential breakout growth indicates XPOVIO is mature and capped in its current indications.
Collapsed 68% YoY from $8.2M in 25Q2. The drop is primarily tied to the December 2025 expiration of Menarini's annual $15.0M development reimbursement obligation, creating a permanent hole in top-line total revenue.
Increased 17% YoY from $11.2M. The elevated expense reflects the punishing terms of the October 2025 refinancing transactions. Interest payments alone eat up 42% of U.S. product revenue.
Guidance
Stable/Decelerating vs FY25's actual total revenue of $146.1M. Achievability depends almost entirely on the core multiple myeloma business maintaining its current run rate, as milestone revenue has dried up.
Stable vs FY25's $114.9M. This implies roughly flat quarterly sequential growth (~$30.6M/quarter), assuming gross-to-net optimizations hold and no further market share is lost to newer bispecifics.
Flat to down slightly vs FY25 ($230.8M actual). The exclusion of 'one-time costs' related to evaluating strategic alternatives suggests headline GAAP expenses will likely come in higher as Centerview Partners executes the restructuring.
Key Questions
The Default Plan
With the September 10th $15.8M payment expected to trigger a liquidity covenant default, are lenders currently offering a waiver, or is a Chapter 11 restructuring actively on the table?
EC-042 Capital Reallocation
Following the failure of the EC-042 trial, how much exact capital will be freed up by pausing investment in endometrial cancer, and will it alter the September liquidity timeline?
FDA Stance on SVR35
Given the mixed SENTRY endpoints (SVR35 met, TSS failed), how specifically did the FDA define the parameters for an accelerated approval, and are they requiring confirmatory overall survival data pre-approval?